搜尋結果
利用化學品、加熱或輻射等方式去除病原體（細菌或病毒）的活性，再將不活化的病原體顆粒製成疫苗。 這種方式安全性高，且易於運輸及儲存，是傳統流感疫苗和A型肝炎疫苗常見的製備方法。
Recruiting加入高端疫苗. 我們重視員工的成長、發展與工作熱情，. 誠摯地歡迎具專業能力與創新思考的您，一起努力為人類健康做出貢獻！. 加入我們. 地 址302 新竹縣竹北市生醫三路68號. 電 話03-668-4866. 傳 真03-668-4865. E-mailinfo@medigenvac.com. 關於高端.
研發與產品 R&D AND PIPELINE MVC focuses on global and regional infectious diseases, and is committed to developing countermeasures for the prevention and treatment of emerging infectious diseases, including COVID-19 vaccine, Enterovirus A17 vaccine, and
On September 28th MVC obtains TFDA's IND approval to conduct phase 2 POC clinical trial in Taiwan. Since the risk of dengue fever increases significantly in Taiwan's elderlies, this randomized, double-blind, placebo-controlled phase 2 clinical trial will include subjects up to 70 years old to verify vaccine's immunity and safety in senior ...
2021/07/19MVC COVID-19 Vaccine Obtains Taiwan EUA Approval. TAIPEI, TAIWAN --July 19th, 2021. Medigen Vaccine Biologics Corp (MVC) obtains Taiwan EUA approval due to MVC's COVID-19 vaccine has fulfilled following EUA standards set by Taiwan's regulatory agencies: 1.For the GMT of MVC-COV1901, the lower bound of 95% confidence interval (CI) is 3 ...
高端疫苗生物製劑股份有限公司
2021年12月27日 · 經本公司了解後，目前北市高端疫苗預約門診已全數額滿，而現場掛號依實際狀況不同，無法確認可否施打，民眾可先電詢聯醫仁愛院區及中興院區、中心綜合醫院、萬芳醫院及景美醫院確認目前狀況，或建議移至外縣市施打。
